Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Rudolph Navari, MD
University of Alabama at Birmingham
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Alabama at Birmingham
Birmingham, Alabama, United States
- Indiana University
Indianapolis, Indiana, United States
- Mayo Clinic
Rochester, Minnesota, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Hospital Sisters Health System (hshs) St. Vincent Hospital
Green Bay, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 12 Jul 2017
- Primary completion
- 12 Jul 2019
- Completion
- 15 Sept 2020
- Last update posted
- 17 Aug 2021
- Registered enrollment
- 30
- Registry id
- NCT03137121
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.